Effect of antihypertensive (pargyline hydrochloride-methyclothiazide) therapy in three types of hypertension: preliminary report after one year of observation.
Fifty patients with elevated blood pressure were classified according to 3 sub-groups as follows: 11 with borderline hypertension, 8 with systolic hypertension, and 31 with diastolic hypertension. So far, they have been observed for one year while being treated with an antihypertensive preparation containing pargyline hydrochloride and methyclothiazide. Response to treatment depended in large measure upon the type of hypertension; the borderline type was virtually unchanged; in the systolic type there was some diminution in the systolic, but less in the diastolic pressure; and in the diastolic type there was a reduction in both systolic and diastolic pressures. Side effects (faintness, nervousness, mouth dryness, insomnia, genitourinary disturbances and elevated blood uric acid level), when they occurred, were usually relieved by appropriate alteration of the antihypertensive drug dosage, by a change in the time of administration, or by adding medication directed at treatment of the side effect. Evaluation of cardiac output before and after therapy showed no change in this parameter. The results suggest: (a) that the antihypertensive effect probably was achieved by diminishing the peripheral resistance rather than by reducing the cardiac output, and (b) that there was no deterioration of myocardial efficiency, as measured by cardiac output, during the one-year period of antihypertensive therapy. More knowledge of the natural history of hypertension in each of the 3 sub-groups is required for better assessment of the influence of antihypertensive therapy on the outcome of the disease. Judgment as to the desirability of initiating therapy can in some measure be based on the classification of patients into appropriate sub-groups.
Campione
K M
KM
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004232:Diuretics; D004338:Drug Combinations; D006801:Humans; D006973:Hypertension / Q000145:classification / Q000188:drug therapy*; D008736:Methyclothiazide / Q000627:therapeutic use*; D010293:Pargyline / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D004232:Diuretics; D004338:Drug Combinations; D049993:Sodium Chloride Symporter Inhibitors; D010293:Pargyline; D008736:Methyclothiazide